Welcome to our dedicated page for Regen Biopharma news (Ticker: RGBPP), a resource for investors and traders seeking the latest updates and insights on Regen Biopharma stock.
Regen Biopharma (RGBPP) is a clinical-stage biotechnology company advancing novel therapies for cancer and autoimmune disorders through small molecule and RNA-based approaches. This news hub provides investors and researchers with timely updates on the company's scientific progress and strategic developments.
Access comprehensive coverage of clinical trial milestones, research collaborations, and regulatory updates related to RGBPP's immunotherapy pipeline. Our curated news collection enables informed tracking of the company's work in immune cell modulation and nucleic acid therapeutics.
Key content categories include updates on preclinical studies, intellectual property developments, and strategic partnerships within the oncology and autoimmune therapy sectors. All content undergoes rigorous verification to ensure accuracy and relevance for stakeholders.
Bookmark this page for streamlined access to Regen Biopharma's latest scientific advancements and corporate announcements. Check regularly for verified updates on their pioneering work in immune system modulation therapies.
Regen BioPharma (RGBP) has provided updates on its planned Phase 1 clinical trial for HemaXellerate™, a stem cell-derived therapy that received FDA clearance. The therapy aims to stimulate bone marrow regeneration, initially targeting aplastic anemia with potential expansion into chemotherapy-induced bone marrow suppression. The company has partnered with a specialized CRO to conduct the trial, which is expected to complete within 12-14 months. The targeted market for chemotherapy-induced bone marrow suppression is valued at over $1 billion annually.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) will present at the Emerging Growth Conference on September 25, 2024, at 4:00 PM Eastern Time. The company, which focuses on developing cell therapies, RNA vaccines, RNA and DNA therapeutics, and small molecule drugs, invites investors, advisors, and analysts to attend this interactive online event.
CEO Dr. David Koos will lead the presentation, providing updates on fiscal and scientific goals, progress on current programs, and the timeline for the anticipated HemaXellerate clinical phase I. Attendees will have the opportunity to ask questions in real-time during the 10-minute presentation.
Interested parties can register for the event through the provided link. An archived webcast will be available on EmergingGrowth.com for those unable to attend live.
Regen BioPharma, Inc. is set to present at the Emerging Growth Conference on May 9, 2024, offering shareholders and investors insights into its Phase 1 clinical study-ready HemaXellerate and preclinical DuraCAR programs. The event aims to provide real-time interaction with the CEO, Dr. David Koos, enabling attendees to ask questions and stay updated on the company's advancements in biotechnology.
FAQ
What is the current stock price of Regen Biopharma (RGBPP)?
What is the market cap of Regen Biopharma (RGBPP)?
